Systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with hypertension: review of the literature and our own data

Cover Page

Cite item

Full Text

Abstract

The goal is to provide an overview of the literature on systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease (COPD) in combination with arterial hypertension (AH) and our own results.Materials and methods. A review of the 56 literature resources on the stated theme is presented. Our own study included 65 patients (50 men and 15 women), of mean age 65.5±8.5 years with COPD stages I-IV in a period of stability of the disease with hypertension 1, 2 and 3rd degree.Results. The state of systemic inflammation and endothelial dysfunction in patients with COPD combined with hypertension according to the literature and evaluated the results of our own research-level markers of inflammatory status and endothelial dysfunction in patients was examined. Revealed were high levels of the studied parameters (hsSRB, sICAM-1, endothelin-1 and SP-selectin) in patients with COPD associated with AH. During the correlation analysis, statistically significant feedbacks activity studied in the index markers forced expiratory volume in 1 second.Conclusion. In patients with COPD combined with hypertension high levels of markers of inflammation and endothelial dysfunction (hsSRB, sICAM-1, endothelin-1 and SP-selectin), which indicate the presence of an active systemic inflammation and endothelial dysfunction in these patients were revealed. In the work carried out it shows that as the deterioration of bronchial obstruction increases the intensity of the markers of inflammation and endothelial dysfunction.

About the authors

S. I Ovcharenko

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: svetftk@mail.ru
д-р. мед. наук, проф. каф. факультетской терапии №1 лечебного фак-та ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 1

Z. N Nersesian

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

ассистент каф. факультетской терапии №1 лечебного фак-та ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 1

References

  1. Задионченко В.С. Артериальная гипертония и хроническая обструктивная болезнь легких - клинико - патогенетические параллели и возможности терапии. Рос. кардиол. журн. 2009; 6: 62-9.
  2. Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная фармакотерапия в кардиологии. 1999; 4: 9-16.
  3. Anthonisen N.R, Connett J.E, Enright P.L, Manfreda J, Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9.
  4. Suylen R.I, Smits J.F, Daemen M.J. Pulmonary artery remodeling difference in hypoxia and monocrotaline induced pulmonary hypertension. Am J Respir Erit Care Med 2008; 157: 1423-8.
  5. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary disease. Circulation 2001; 104: 263-8.
  6. Lucher T.F, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118: 81-90.
  7. Ridker P, Cannon C, Morrow D.et al. Pravastatin or Atorvastatin Evaluation and In fection Therapy - trombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20.
  8. Sin D.D, Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-9.
  9. Nosratola D, Bernardo R. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrology 2006; 2 (10): 582- 93.
  10. Repine J.E, Bast A, Lankhorst L. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-57.
  11. Henning B, Diana J.N, Toborek M, Mc Clain C.J. Influence of nutrients and cytokines on endothelial cell metabolism. J Am Coll Nutr 1994; 13: 224-31.
  12. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clinica Chimica Acta 2006; 368: 33-47.
  13. Corrado E, Rizzo M, Tantillo R et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow - up study. Stroke 2006; 37: 482-6.
  14. Ridker P.M, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 1998; 46: 391-5.
  15. Ridker P.M, Hennekens C.H. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
  16. Saetta M, Baraldo S, Corbino L et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-1.
  17. Bautista L.E, Lopez-Jaramillo P, Vera L.M, Casas J.P. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-61.
  18. Van Der Meer I.M, de Maat M.P, Hak A.E. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the: Rotterdam Study. Stroke 2002; 33: 2750-5.
  19. Вельков В.В. С-реактивный белок в лабораторной диагностике острых воспалений и в оценке рисков сосудистых патологий. Клинико - лабораторный консилиум. 2008; 2 (21): 37-48.
  20. Genest J, Mc Pherson J, Frohlich R et al. 2009 Canadian Cardiovascular Society. Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009; 25: 567-79.
  21. Pearson T.A, Mensah G.A, Alexander R.W et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107: 499-511.
  22. Ridker P.M, Danielson E, Fonseca F.A.H et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.
  23. Wang C, Yatsuya H, Tamakoshi K et al. Positive association between high - sensitivity C-reactive protein and incidence of type 2 diabetes mellitus in Japanese workers: 6- year follow - up. Diabetes 2013; 29 (5): 398-405.
  24. Wilson P.W.F et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circulation: cardiovascular quality and outcomes 2008; 1: 92-7.
  25. Shichiri M et аl. Plаsmа endоthelin levels in hypertensiоn аnd chrоnic renаlfаilure. Hypertensiоn; 15: 493-6.
  26. Springеr T.А. Trаffic signаls fоr lymphоcyte recirculаtiоn аnd leukоcyte emigrаtiоn: The multistep pаrаdigm. Cell 1994; 76: 301-14.
  27. Искандарова Л.Р., Хайбулина Н.Г., Амирова А.Р. и др. Показатели межклеточных молекул адгезии, иммунной системы при артериальной гипертонии. Современные наукоемкие технологии. 2005; 10: 43-4.
  28. Gearing A.J.H, Newman W. Circulating adhesion molecules in disease. Immunology Today 1993; 14 (10): 506-12.
  29. Grabie N, Tarrio M.L, Newton G et al. Foxp3+inducible regulatory T Cells suppress endothelial activation and leukocyte recruitment. J Immunol 2011; 187: 3521-9.
  30. Ceriello A, Falleti E, Motz E et al. Hyperglycemia - induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998; 30: 146-9.
  31. Meydani M. Omega-3 fatty acids alter soluble markers of endothelial function in coronary heart disease patients. Nutr Rev 2000; 58: 56-9.
  32. Pontiroli A.E, Pizzocri P, Koprivec D. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol 2004; 150: 195-200.
  33. Weyer C, Yudkin J.S, Stehouwer C.D et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-42.
  34. Riise G.C, Larsson S, Lofdalh G.G, Andersson В.A. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 1994; 7: 167-37.
  35. David M.P. Endothelin, Angiotensin, and Oxidative Stress in Hypertension. Hypertension 2005; 45: 477.
  36. Недогода С.В. Сосудистая жесткость и скорость распространения пульсовой волны как плацдарм и мишень для фармакотерапии. В помощь практическому врачу. 2012; 1 (41): 113-6.
  37. Laurent S, Boutouyrie P, Asmar R, Gautier I. Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients. Hypertension. 2001; 37: 1236-41.
  38. Гельцер Б.И. Оценка артериальной ригидности у больных хронической обструктивной болезнью легких. Пульмонология. 2008; 1: 38.
  39. Sabit R, Bolton C.E, Edwards P.H, Pettit R.J. Stiffness and Osteoporosis in Chronic Obstructive Pulmonary Disease. Am J Resp Crit Care Med 2007; 175: 1259-65.
  40. Мухарлямов Н.М., Саттбеков Ж.С., Сучков В.В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких. Кардиология. 1974; 12 (34): 55-61.
  41. Палеев Н.Р. Существует ли «пульмогенная гипертензия»? Кардиология. 2002; 6: 51-3.
  42. Александров А.И. Легочная гемодинамика и функциональное состояние сердца при хронических неспецифических заболеваниях легких. Автореф. дис. … д - ра мед. наук. Спб., 1992.
  43. Бобров В.А. Состояние миокарда, гемодинамика и прессорные гуморальные субстанции у больных бронхиальной астмой и артериальной гипертензией. Клин. медицина. 1989; 11: 31-5.
  44. Глезер Г.А. Артериальная гипертония. M.: Издательство Атмосфера, 1996.
  45. Серебрякова В. И. Клинико - патологические особенности нейроэндокринной регуляции при сочетании артериальной гипертензии с лабильной и стабильной обструкцией бронхов в возрастном и половом аспекте, коррекция выявленных нарушений. Автореф. дис. ... д - ра мед. наук. Спб, 1998.
  46. Dinh-Xuan A.T, Higenbottam T.W, Glelland G.A et al. Impairment of endothelium - dependent pulmonary - artery relaxation in chronic obstructive lung disease. N Engl Med J 1991; 324: 1539.
  47. Schiffrin E.L. The endothelium of resistance arteries: physiology and role in hypertension. Prostaglandins Leukot Essent Fatty Acids 1996; 54 (1): 17-25.
  48. Shimokawa H. Endothelial dysfunction in hypertension. J Atheroscler Thromb 1998; 4 (3): 118-27.
  49. Simon A, Castro A, Kaski J.C. Assessment of endothelial dysfunction and its clinical usefulness. Rev Esp Cardiol 2001; 54 (2): 211-7.
  50. Ribeiro O.F, Alves A.J, Teixeira M et al. Endothelial function and atherosclerosis: circulatory markers with clinical usefulness. Rev Port Cardiol 2009; 28 (10): 1121- 51.
  51. Kinlаy S, Behrendt D, Wаinsteinetаl M. Rоleof Endоthelin-1 in the Аctive Cоnstrictiоn оf Humаn Аtherоsclerоtic Cоrоnаry Аrteries. Circulаtiоn. 2001; 104: 1114.
  52. Rongen G.A, Smits P, Thien T. Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical implications. Neth J Med 1994; 44 (1): 26-35.
  53. Libby P, Ridrer P.M, Masseri A. Inflammation and Atherosclerosis. Circulation 2002; 105: 1135-43.
  54. Oelsner E.C, Pоttinger T.D, Burkаrt K.M, Аllisоn M. Adhesiоnmоlecules, endоthelin-1 аnd lung functiоni n seven pоpulаtiоn - bаsedcоhоrts. Biоmаrkers 2013; 18 (3): 196- 203.
  55. Wаlter R.E, Wilk J.B, Lаrsоn M.G, Vаsаn R.S. Systemic inflаmmаtiоn аnd CОPD: the Frаminghаm Heart Study. Chest 2008; 133 (1): 19-25.
  56. Zhonghuа Jie He He, Hu Xi Zа Zhi. Integrin - аssоciаted prоteins in blood plаsmа оf pаtients with аcutееxаcerbаtiоn оf chrоnic оbstructive pulmоnаry disease. Article in Chinese 2010; 33 (4): 265-7.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies